Filtros de búsqueda

Lista de obras de Antonio Palumbo

A comparison of allografting with autografting for newly diagnosed myeloma

artículo científico publicado en 2007

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

artículo científico publicado en 2008

A new combination for advanced multiple myeloma

artículo científico publicado en 2011

A new standard of care for elderly patients with myeloma

artículo científico publicado en 2007

A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.

artículo científico publicado en 2018

Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2015

Age and aging in blood disorders: multiple myeloma

artículo científico publicado en 2014

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

artículo científico publicado en 2013

Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.

artículo científico publicado en 2015

Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates

artículo científico publicado en 2008

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

artículo científico publicado en 2011

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

scientific article published on 31 January 2011

Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?

artículo científico publicado en 2015

Autologous transplantation and maintenance therapy in multiple myeloma

artículo científico publicado en 2014

Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.

artículo científico publicado en 2014

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

artículo científico publicado en 2016

Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.

artículo científico publicado en 2013

Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide

artículo científico publicado en 2005

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

artículo científico publicado en 2010

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

artículo científico publicado en 2014

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

artículo científico publicado en 2013

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

artículo científico publicado en 2010

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

artículo científico publicado en 2010

Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study

artículo científico publicado en 2012

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

scientific article published on 05 February 2014

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

artículo científico publicado en 2007

Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study

artículo científico publicado en 2014

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

artículo científico publicado en 2010

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

artículo científico publicado en 2014

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2012

Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.

artículo científico publicado en 2006

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

artículo científico publicado en 2016

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

artículo científico publicado en 2007

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

artículo científico publicado en 2014

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors

artículo científico publicado en 2014

Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply

scientific article published on 29 March 2016

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

artículo científico publicado en 2017

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

artículo científico publicado en 2016

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

artículo científico publicado en 2020

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

artículo científico publicado en 2017

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

artículo científico publicado en 2017

Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al

artículo científico publicado en 2013

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

artículo científico publicado en 2015

Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies

artículo científico publicado en 2014

Clinical characteristics of patients with relapsed multiple myeloma

artículo científico publicado en 2015

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

artículo científico publicado en 2015

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

artículo científico publicado en 2014

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

artículo científico publicado en 2011

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

artículo científico publicado en 2011

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

artículo científico publicado en 2011

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.

scientific article published on August 2010

Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts

artículo científico publicado en 2008

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

article

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

artículo científico publicado en 2015

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

scientific article published on 14 September 2018

Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study

scientific article published on 01 June 2005

Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.

artículo científico publicado en 2014

Current multiple myeloma treatment strategies with novel agents: a European perspective

scientific article published on 19 January 2010

Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.

artículo científico publicado en 2012

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

artículo científico publicado en 2005

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

scientific article published on 13 February 2020

Diagnosis and therapy of multiple myeloma

artículo científico

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.

artículo científico publicado en 2015

Downregulation of p53-inducible microRNAs 192 , 194 , and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

article

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development

artículo científico publicado en 2010

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis

artículo científico publicado en 2018

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

artículo científico publicado en 2015

Efficacy and safety of bortezomib in patients with plasma cell leukemia

artículo científico publicado en 2007

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

artículo científico publicado en 2010

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

artículo científico publicado en 2004

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2015

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

artículo científico publicado en 2017

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

artículo científico publicado en 2016

European Myeloma Network guidelines for the management of multiple myeloma-related complications

artículo científico publicado en 2015

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

artículo científico publicado en 2010

European perspective on multiple myeloma treatment strategies in 2014

artículo científico publicado en 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses

artículo científico publicado en 2012

Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma

artículo científico publicado en 2012

Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.

artículo científico publicado en 2011

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

artículo científico publicado en 2013

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

artículo científico publicado en 2019

First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective

artículo científico publicado en 2009

Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles

article

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis

artículo científico publicado en 2015

Have drug combinations supplanted stem cell transplantation in myeloma?

artículo científico

Have drug combinations supplanted stem cell transplantation in myeloma?

artículo científico publicado en 2012

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

artículo científico publicado en 2016

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

artículo científico publicado en 2014

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

scientific article published on February 2014

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

artículo científico publicado en 2013

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

scholarly article by Anjan Thakurta et al published 14 March 2019 in Blood

High-risk myeloma: when to transplant-or not.

artículo científico publicado en 2013

How I treat fragile myeloma patients.

artículo científico

How to manage neutropenia in multiple myeloma

artículo científico

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

scientific article published on January 2009

How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.

artículo científico publicado en 2011

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies

scientific article published on 19 November 2018

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma

artículo científico publicado en 2017

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V 9V 2 T Cells, CD8+ T Cells, Regulatory T Cells, and Dendritic Cells

artículo científico publicado en 2011

Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point

artículo científico publicado en 2015

Incorporating novel agents in the management of elderly myeloma patients

artículo científico publicado en 2013

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.

artículo científico publicado en 2012

Initial treatment of nontransplant patients with multiple myeloma

artículo científico publicado en 2013

Initial treatment of transplant-ineligible patients in multiple myeloma

artículo científico publicado en 2013

Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma

scientific article published on 01 May 2006

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

scientific article published on 20 July 2004

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

artículo científico publicado en 2016

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

artículo científico publicado en 2014

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

artículo científico publicado en 2014

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

scientific article published on 09 November 2018

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

artículo científico publicado en 2006

Investigational treatments for multiple myeloma

artículo científico publicado en 2006

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

artículo científico publicado en 2017

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

artículo científico publicado en 2017

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis

artículo científico publicado en 2019

Lenalidomide and its role in the management of multiple myeloma

artículo científico publicado en 2008

Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

artículo científico publicado en 2016

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Lenalidomide in the treatment of lymphoproliferative disorders and multiple myeloma

artículo científico publicado en 2013

Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives.

artículo científico publicado en 2013

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

artículo científico publicado en 2013

Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma

artículo científico publicado en 2010

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.

artículo científico

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

scientific article published on 03 October 2019

Lenalidomide: a new therapy for multiple myeloma

artículo científico publicado en 2008

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

artículo científico publicado en 2011

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.

artículo científico publicado en 2009

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

artículo científico publicado en 2014

MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?

artículo científico

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis

scientific article published on 19 April 2018

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

artículo científico publicado en 2010

Management of disease- and treatment-related complications in patients with multiple myeloma.

artículo científico publicado en 2010

Management of myeloma: an Italian perspective

artículo científico publicado en 2011

Management of older adults with multiple myeloma

artículo científico publicado en 2013

Management of older patients with multiple myeloma.

artículo científico publicado en 2011

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study

scientific article published on 23 March 2020

Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

artículo científico publicado en 2009

Melphalan and its role in the management of patients with multiple myeloma.

artículo científico publicado en 2007

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results

artículo científico publicado en 2009

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

artículo científico publicado en 2007

Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study

artículo científico publicado en 2010

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

artículo científico publicado en 2010

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

artículo científico publicado en 2008

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

artículo científico publicado en 2015

Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

scientific article published on 13 October 2016

Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

scientific article published on 18 December 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

artículo científico publicado en 2009

Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.

artículo científico

Monoclonal gammopathy of undetermined significance: a consensus statement

artículo científico publicado en 2010

Multiple Myeloma

artículo científico publicado en 2011

Multiple myeloma in the very old: an IASIA conference report

artículo científico publicado en 2014

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

artículo científico publicado en 2011

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

scientific article published on 26 March 2011

Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents

artículo científico publicado en 2015

Multiple myeloma: is a shift toward continuous therapy needed to move forward?

artículo científico publicado en 2015

MyelomA Genetics International Consortium

artículo científico

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

artículo científico publicado en 2008

New approaches to management of multiple myeloma.

artículo científico publicado en 2014

New drugs for treatment of multiple myeloma.

artículo científico publicado en 2004

New pharmacotherapy options for multiple myeloma

artículo científico

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

artículo científico publicado en 2008

Novel investigational drugs active as single agents in multiple myeloma.

artículo científico publicado en 2017

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

scientific article published on 30 January 2018

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

scientific article published on 07 February 2019

Optimal management of elderly patients with myeloma

artículo científico

Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach

artículo científico publicado en 2016

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

artículo científico publicado en 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

artículo científico publicado en 2006

Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma

artículo científico publicado en 2002

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma

artículo científico publicado en 2005

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

artículo científico publicado en 2008

Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.

artículo científico publicado en 2010

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations

article

PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy.

artículo científico publicado en 2003

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

artículo científico publicado en 2012

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

artículo científico publicado en 2011

Pharmacophore modeling technique applied for the discovery of proteasome inhibitors

artículo científico

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

artículo científico publicado en 2016

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

artículo científico publicado en 2017

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

artículo científico publicado en 2014

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

artículo científico publicado en 2014

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial

scientific article published on 04 April 2019

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

artículo científico publicado en 2016

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2012

Plasma cell leukemia: update on biology and therapy.

artículo científico publicado en 2016

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

artículo científico publicado en 2015

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data

artículo científico publicado en 2014

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

artículo científico publicado en 2016

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

artículo científico publicado en 2013

Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

artículo científico publicado en 2013

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

artículo científico publicado en 2016

Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

artículo científico publicado en 2011

Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma

artículo científico

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

artículo científico publicado en 2009

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp

artículo científico publicado en 2015

Primary plasma cell leukemia in the era of new drugs: has something changed?

artículo científico publicado en 2011

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

scientific article published on 09 January 2019

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

artículo científico publicado en 2018

Proteasome inhibitors in multiple myeloma: 10 years later

artículo científico

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

artículo científico publicado en 2016

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.

artículo científico publicado en 2017

Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma

scientific article published on 10 October 2019

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

artículo científico publicado en 2016

Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests

scientific article published on 01 June 2002

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

scientific article published on 09 March 2020

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

artículo científico publicado en 2010

Review of thalidomide in the treatment of newly diagnosed multiple myeloma.

artículo científico publicado en 2007

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

artículo científico publicado en 2010

Role of consolidation/maintenance therapy in multiple myeloma.

artículo científico

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

artículo científico publicado en 2015

Role of thalidomide in previously untreated patients with multiple myeloma.

scientific article published on October 2008

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

artículo científico publicado en 2012

Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.

artículo científico publicado en 2009

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

scientific article published on 27 September 2011

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

artículo científico publicado en 2016

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

artículo científico publicado en 2012

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

artículo científico publicado en 2014

Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma

artículo científico publicado en 2009

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival

scientific article published on March 2011

Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma

scientific article published on 05 December 2011

Stem Cell Transplantation in Multiple Myeloma.

artículo científico publicado en 2016

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

artículo científico publicado en 2016

Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins

artículo científico

Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.

artículo científico publicado en 2004

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

artículo científico publicado en 2010

Survival and years of life lost in different age cohorts of patients with multiple myeloma.

artículo científico publicado en 2010

Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network

artículo científico publicado en 2014

Sustained disease control in transplant-ineligible patients: the role of continuous therapy

scientific article published on 01 November 2012

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

artículo científico publicado en 2015

Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients

scientific article published on 18 November 2010

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

artículo científico publicado en 2008

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

artículo científico publicado en 2011

Thalidomide for treatment of multiple myeloma: 10 years later

artículo científico publicado en 2008

Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant

artículo científico publicado en 2005

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma

artículo científico publicado en 2007

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective

artículo científico publicado en 2016

The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status

artículo científico publicado en 2014

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

artículo científico publicado en 2014

The current status and future of multiple myeloma in the clinic

artículo científico publicado en 2010

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens

artículo científico publicado en 2010

The future role of thalidomide in multiple myeloma

artículo científico publicado en 2005

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

artículo científico publicado en 2015

The impact of response on bone-directed therapy in patients with multiple myeloma.

artículo científico publicado en 2013

The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma

artículo científico

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

artículo científico

The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents

artículo científico

The treatment of the elderly multiple myeloma patients

artículo científico publicado en 2007

Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs

artículo científico publicado en 2010

Thromboembolic events with lenalidomide-based therapy for multiple myeloma

artículo científico publicado en 2008

Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.

artículo científico publicado en 2007

Towards a new standard of care for patients with myeloma?

artículo científico publicado en 2009

Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.

artículo científico publicado en 2013

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response

artículo científico publicado en 2018

Treatment of Newly Diagnosed Elderly Multiple Myeloma.

artículo científico publicado en 2016

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016

Treatment of newly diagnosed multiple myeloma

artículo científico publicado en 2008

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

artículo científico publicado en 2010

Treatment of relapsed multiple myeloma

artículo científico publicado en 2015

Treatment of relapsed/refractory multiple myeloma

artículo científico publicado en 2009

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

artículo científico publicado en 2010

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

artículo científico publicado en 2016

Update on recent developments for patients with newly diagnosed multiple myeloma

artículo científico publicado en 2008

Update on the use of defibrotide

artículo científico publicado en 2012

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

artículo científico publicado en 2013

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda